Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 16/20 | 0.48 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.35 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7598637 | 0.86 | SSTR4 (0.50) | SSTR4CTSCRENSSTR1SSTR2 | |
| SCHEMBL20711876 | 0.81 | SSTR4 (0.55) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL29516296 | 0.81 | SSTR4 (0.55) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL9303399 | 0.78 | HPGD (0.51) | TSHR | |
| SCHEMBL9303388 | 0.78 | HPGD (0.51) | TSHR | |
| SCHEMBL9303877 | 0.77 | TSHR (0.50) | TSHR | |
| SCHEMBL9303874 | 0.77 | TSHR (0.50) | TSHR | |
| SCHEMBL4956052 | 0.77 | SSTR4 (0.52) | SSTR4CTSCRENSSTR1SSTR2 | |
| SCHEMBL29789518 | 0.75 | TSHR (0.44) | TSHR | |
| SCHEMBL21625333 | 0.75 | SSTR4 (0.51) | SSTR4CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128434-A1 | Alpha-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | ZIMMERMAN MARY P (US) | 2002-09-12 | — | — | US | disclosed |
| US-6147188-A | IRREVERSIBLE CATHEPSIN OR CALPAIN INHIBITORS | PROTOTEK, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0863883-A1 | ALPHA-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS | PROTOTEK, INC., (US) | 1998-09-16 | — | — | EP | disclosed |
| EP-0863883-A4 | — | — | 1998-09-16 | — | — | EP | disclosed |
| US-5714484-A | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | PROTOTEK, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| WO-1996040647-A1 | α-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS | PROTOTEK, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128434-A1 | Alpha-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | CPN1, CTRL, SERPINB1 | SSTR4 4772/4885CTSC 11/4885REN 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.